Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PTGX Protagonist Therapeutics

Not Yet Opened 06-17 16:00:00 EDT

111.44

+0.80

+0.72%

盘后111.44

+0.000.00%

19:37 EDT

High113.47	Low110.11	Vol742.53K
Open110.84	D1 Closing110.64	Amplitude3.04%
Mkt Cap7.17B	Tradable Cap4.81B	Total Shares64.31M
T/O82.90M	T/O Rate1.72%	Tradable Shares43.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PTGX","market":"US","secType":"STK","nameCN":"Protagonist Therapeutics","latestPrice":111.44,"timestamp":1781726400000,"preClose":110.64,"halted":0,"volume":742531,"hourTrading":{"tag":"盘后","latestPrice":111.44,"preClose":111.44,"latestTime":"19:37 EDT","volume":72452,"amount":8074047.29,"timestamp":1781739424295,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.007230657989877053,"floatShares":43154809,"shares":64305185,"eps":-1.791415,"marketStatus":"Not Yet Opened","change":0.8,"latestTime":"06-17 16:00:00 EDT","open":110.84,"high":113.47,"low":110.11,"amount":82903768.812626,"amplitude":0.030369,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.791415,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781769600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1470888000000,"exchange":"NASDAQ","adjPreClose":110.64,"preHourTrading":{"tag":"盘前","latestPrice":110.1,"preClose":110.64,"latestTime":"09:22 EDT","volume":13,"amount":1432.03008,"timestamp":1781702550404,"change":-0.54,"changeRate":-0.004881,"amplitude":0.010304},"postHourTrading":{"tag":"盘后","latestPrice":111.44,"preClose":111.44,"latestTime":"19:37 EDT","volume":72452,"amount":8074047.29,"timestamp":1781739424295,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.314359,"impliedVol":0.514,"impliedVolPercentile":0.6653},"requestUrl":"/m/hq/s/PTGX/tweets","defaultTab":"tweets","newsList":[{"id":"2644767432","title":"Protagonist Therapeutics grants inducement equity awards for 18,700 shares at $112.46 strike","url":"https://stock-news.laohu8.com/highlight/detail?id=2644767432","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644767432?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:00","pubTimestamp":1781640017,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics granted inducement equity awards on June 15, 2026 to three newly hired employees.Awards total stock options for 14,800 shares, priced at $112.46, plus 3,900 restricted stock units.Options vest over four years: 25% after one year, then monthly over the next three years; RSUs vest 25% annually.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL704zyQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642256339","title":"Top Protagonist Therapeutics Insider Makes a Major Move With His Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2642256339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642256339?lang=en_us&edition=fundamental","pubTime":"2026-06-12 10:09","pubTimestamp":1781230180,"startTime":"0","endTime":"0","summary":"New insider activity at Protagonist Therapeutics ( ($PTGX) ) has taken place on June 11, 2026. Director William Waddill of Protagonist Therapeutics...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-protagonist-therapeutics-insider-makes-a-major-move-with-his-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-protagonist-therapeutics-insider-makes-a-major-move-with-his-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642230865","title":"Protagonist Therapeutics director William D. Waddill disposes of USD 969,120 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2642230865","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642230865?lang=en_us&edition=fundamental","pubTime":"2026-06-12 07:07","pubTimestamp":1781219249,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics director William D. Waddill sold 9,000 common shares on June 10 at USD 107.68, cutting his direct stake to 7,825 shares.He acquired 9,000 shares the same day via option exercises priced at USD 11.8 and USD 16.54.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL23616q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Protagonist Therapeutics director William D. Waddill disposes of USD 969,120 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640135353","title":"Could New Rusfertide Data Presentations Subtly Reframe Protagonist Therapeutics' (PTGX) Core Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2640135353","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640135353?lang=en_us&edition=fundamental","pubTime":"2026-06-04 09:18","pubTimestamp":1780535882,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics recently highlighted that four abstracts on rusfertide in polycythemia vera, including Phase 3 VERIFY and long-term Phase 2 data, will be presented at the 2026 European Hematology Association Congress, while management also appeared at the Jefferies Global Healthcare Conference in New York.\nThe new data cuts from VERIFY and the long-running REVIVE and THRIVE extension studies offer a deeper look at rusfertide’s efficacy, safety and potential impact on cytoreductive...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/could-new-rusfertide-data-presentations-subtly-reframe-prota","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/could-new-rusfertide-data-presentations-subtly-reframe-prota","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640296052","title":"Protagonist Therapeutics director William D. Waddill disposes of 9,000 common shares worth $896,760","url":"https://stock-news.laohu8.com/highlight/detail?id=2640296052","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640296052?lang=en_us&edition=fundamental","pubTime":"2026-06-02 06:32","pubTimestamp":1780353121,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics director William D. Waddill sold 9,000 common shares at USD 99.64 on May 29, 2026.Sale followed a 9,000-share option exercise at USD 11.8, lifting his direct holdings to 16,825 shares before the sale.Waddill ended the day with 7,825 common shares, held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL4jHRGT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Protagonist Therapeutics director William D. Waddill disposes of 9,000 common shares worth $896,760","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638298667","title":"Protagonist Therapeutics CEO Patel to speak at Jefferies Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2638298667","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638298667?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:05","pubTimestamp":1779966351,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics is set for fireside chats at two healthcare investor conferences in June 2026.Jefferies Global Healthcare Conference in New York on June 3, 2026 at 9:55 a.m. ET.Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 10, 2026 at 9:20 a.m. ET.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL4NVbd5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","PTGX","LU0251131958.USD","LU1868837300.USD","LU1791807156.HKD","LU0868494617.USD","LU1868836757.USD","LU1894683264.USD","LU2471134879.HKD","LU1868836591.USD","GSX","LU0742534661.SGD","LU2237443549.SGD","BK4550","LU1668664300.SGD","LU2265009873.SGD","BK4516","IE00BSNM7G36.USD","LU0106831901.USD","IE00B19Z3581.USD","LU2237443382.USD","BK4504","LU1868836914.USD","LU1868837136.USD","BK4552","LU2237443895.HKD","LU1804176565.USD","LU2237443978.SGD","LU2237443622.USD","LU0251142724.SGD","LU0868494708.USD","LU0345770993.USD","BK4533","IE0004086264.USD","BK4585","BK4127","LU2471134952.CNY","LU2750360997.AUD","LU2750360641.GBP","LU2471134523.USD","LU0048573561.USD","IE00B19Z3B42.SGD","LU2237443465.HKD","LU0061475181.USD","IE0004091025.USD","LU0942090050.USD","LU2237438978.USD","IE0002270589.USD","LU2471134796.USD","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638669444","title":"J&J Mastered Cancer Biotech Deals on the Cheap. Can it Stay on the Cutting Edge? -- Heard on the Street -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2638669444","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638669444?lang=en_us&edition=fundamental","pubTime":"2026-05-28 17:30","pubTimestamp":1779960600,"startTime":"0","endTime":"0","summary":"Johnson & Johnson seems to have perfected the art of the biotech deal.Rather than spending billions on acquisitions, it has built much of its pharma empire through partnerships that capture huge upside for bargain prices.But there's a catch. A biotech partnership is a bit like an open relationship: Your partner can always fall in love with someone else.It's early days, but Big Pharma has been racing to own the technology. AbbVie, Bristol-Myers Squibb, AstraZeneca and Gilead have all made acquisitions in the space. Eli Lilly alone has agreed to spend more than $9 billion on two in-vivo companies in the past year. J&J tried to get ahead by joining up with Kelonia, a startup that engineered a virus to selectively target T cells inside the body. Then Lilly last month agreed to pay up to $7 billion to buy Kelonia outright -- based on data from a handful of patients -- and J&J's in-vivo partner suddenly belonged to a rival. A J&J spokesperson said in an email that in-vivo CAR-T remains one o","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0472753341.HKD","LU0738911758.USD","LU1074936037.SGD","PTGX","SG9999001440.SGD","LU1934455863.HKD","BK4534","IE00BGHQF631.EUR","HK0000320223.HKD","LU2602419157.SGD","LU1244550494.USD","ABBV","LU1585245621.USD","LU0057025933.USD","JNJ","LU0122379950.USD","LU1551013342.USD","LU1674673691.USD","LU1989771016.USD","LU1935042991.SGD","HK0000306685.HKD","LU0820561909.HKD","LU1430594728.SGD","LU1280957306.USD","SG9999011175.SGD","SG9999002224.SGD","LU0426417589.USD","LU2750360641.GBP","01548","XBI","LEGN","LU0965509283.SGD","LU1043141123.HKD","LU2417539215.USD","LU0203347892.USD","LU0345770308.USD","BK1141","LU0795875086.SGD","LU2089284900.SGD","BK4007","CAR","LU1291159041.SGD","LU2089283258.USD","LU0456855351.SGD","IE0000B7K699.USD","LU0708994859.HKD","LU1718418525.SGD","LU0545562505.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333285","title":"Genvor names Donald Kalkofen chief financial officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333285","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333285?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:01","pubTimestamp":1779364862,"startTime":"0","endTime":"0","summary":"Genvor appointed Donald Kalkofen as chief financial officer on May 21, 2026, tasking him with financial strategy as it advances commercialization across agriculture, human health, and wellness.Kalkofen most recently served as CFO of Alpha Cognition, where he led preparations for its NASDAQ listing and built out banking, audit committee, and investor relations functions.He previously held CFO roles at Protagonist Therapeutics, Symantec, and West Coast Bancorp, where he took the bank public on NASDAQ.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL980qW7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACOG","IE00BKPKM429.USD","SG9999014039.USD","BK4112","LU2095319765.USD","NDAQ","SG9999014021.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","PTGX","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","GNVR","SG9999014005.SGD","BK4588","SG9999014013.SGD","LU2210150020.SGD","LU0314104364.USD","IE00BGHQF748.EUR","BK4139","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717821","title":"Analysts Offer Insights on Healthcare Companies: Adlai Nortye Ltd. Sponsored ADR (ANL), Protagonist Therapeutics (PTGX) and Nuvalent (NUVL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717821","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717821?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:12","pubTimestamp":1778760777,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adlai Nortye Ltd. Sponsored ADR (ANL), Protagonist T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-adlai-nortye-ltd-sponsored-adr-anl-protagonist-therapeutics-ptgx-and-nuvalent-nuvl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-adlai-nortye-ltd-sponsored-adr-anl-protagonist-therapeutics-ptgx-and-nuvalent-nuvl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","ANL","BK4539","IE00BZ199S13.USD","BK4585","NUVL","BK4137","HCSG","LU0029874061.USD","XBI","XLV","LU0128526141.USD","LABU","BK4581","PTGX","LU2133065610.SGD","ALN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635964229","title":"Protagonist Therapeutics CEO Dinesh Patel disposes of USD 7.51 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2635964229","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635964229?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:28","pubTimestamp":1778628518,"startTime":"0","endTime":"0","summary":"Dinesh V. Patel, President and CEO, exercised stock options for 75,000 shares at USD 21.58 on May 12, 2026.Patel sold 75,000 shares at a weighted average price of USD 100.12 on same day.Directly held common stock ended at 523,478 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL2Sd4Xb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Protagonist Therapeutics CEO Dinesh Patel disposes of USD 7.51 million common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634251512","title":"Protagonist Therapeutics director Bryan Giraudo disposes 59,130 shares worth $5.92 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634251512","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634251512?lang=en_us&edition=fundamental","pubTime":"2026-05-12 08:26","pubTimestamp":1778545596,"startTime":"0","endTime":"0","summary":"Director Bryan Giraudo reported sales of 47,130 Protagonist Therapeutics common shares on May 7-8, including 36,000 shares at USD 100.14 weighted average and 5,130 shares at USD 100.He also exercised stock options for 36,000 shares on May 7 at USD 6.45 to USD 6.98 per share.Directly held common shares stood at 12,695 following transactions.Bryan & Courtney Giraudo Trust reported 0 shares following separate sales of 12,000 shares on May 7 at USD 100.07 and 6,000 shares on May 8 at USD 100.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and E","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL8SB7R5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Protagonist Therapeutics director Bryan Giraudo disposes 59,130 shares worth $5.92 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634440939","title":"Protagonist Therapeutics (PTGX) Receives a Buy from Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2634440939","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634440939?lang=en_us&edition=fundamental","pubTime":"2026-05-10 21:37","pubTimestamp":1778420250,"startTime":"0","endTime":"0","summary":"Citi analyst Geoff Meacham maintained a Buy rating on Protagonist Therapeutics on May 7 and set a price target of $130.00. The company’s shares clo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/protagonist-therapeutics-ptgx-receives-a-buy-from-citi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/protagonist-therapeutics-ptgx-receives-a-buy-from-citi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633148101","title":"Protagonist Therapeutics Q1 Profit Challenges Trailing Loss Narrative For PTGX Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2633148101","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633148101?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:34","pubTimestamp":1778150089,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) opened 2026 with Q1 revenue of US$56.4 million, Basic EPS of US$0.06 and net income of US$3.8 million, while trailing 12 month figures show revenue of US$74.1 million, a Basic EPS loss of US$1.79 and a net loss of US$114.7 million. Over the past year, the company has seen quarterly revenue move between US$4.7 million and US$170.6 million, alongside Basic EPS that has ranged from a US$2.11 profit to a US$0.69 loss. These figures give investors a broad set of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-q1-profit-challenges-trailing-loss","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-q1-profit-challenges-trailing-loss","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PTGX","ISBC","BK4211","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633192046","title":"Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2633192046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633192046?lang=en_us&edition=fundamental","pubTime":"2026-05-07 14:36","pubTimestamp":1778135799,"startTime":"0","endTime":"0","summary":"Goldman Sachs raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $97 and keeps a Neutral rating on the shares. The pric...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-price-target-raised-to-110-from-97-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-price-target-raised-to-110-from-97-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633198514","title":"Protagonist Therapeutics management to meet virtually with Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2633198514","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633198514?lang=en_us&edition=fundamental","pubTime":"2026-05-07 10:51","pubTimestamp":1778122264,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on May 12-13 hosted by Clear Street. Published first on TheFly – the ultimate source for real-time, market-moving breaki...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-management-to-meet-virtually-with-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-management-to-meet-virtually-with-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633160380","title":"Protagonist Therapeutics participates in a conference call with JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2633160380","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633160380?lang=en_us&edition=fundamental","pubTime":"2026-05-07 10:17","pubTimestamp":1778120249,"startTime":"0","endTime":"0","summary":"Conference call with management will be held on May 6 at 2 pm hosted by JPMorgan.Webcast Link Published first on TheFly – the ultimate source for r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-participates-in-a-conference-call-with-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-participates-in-a-conference-call-with-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PGF","IE00BKVL7J92.USD","LU1548497426.USD","LU1974910355.USD","BK4566","LU0942090050.USD","LU1496350502.SGD","LU0070302665.USD","LU2746668461.USD","LU1894683264.USD","IE0034235295.USD","LU0496365809.HKD","LU1670627923.USD","LU2552382058.USD","LU2462157665.USD","LU0149725797.USD","IE00B1BXHZ80.USD","LU0238689110.USD","LU1267930490.SGD","LU2417539215.USD","LU0256863811.USD","LU0868494617.USD","LU0859254822.USD","BK4581","IE00BLSP4239.USD","LU1629891620.HKD","LU0211326839.USD","LU0689472784.USD","LU0211331839.USD","JPMO","LU1261432733.SGD","LU1084165304.USD","BK4550","IE00BKDWB100.SGD","LU1914381329.SGD","LU0203347892.USD","PTGX","IE00BJLML261.HKD","LU2237443622.USD","BK4207","LU1894683348.USD","JPM","LU1116320901.HKD","LU1119994496.HKD","LU1670628061.USD","LU0976567544.SGD","JPO","LU0256863902.USD","LU0820562030.AUD","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633273130","title":"H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633273130","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633273130?lang=en_us&edition=fundamental","pubTime":"2026-05-07 00:37","pubTimestamp":1778085440,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $117.00. Tsao covers the H...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633783139","title":"Wedbush Adjusts Price Target on Protagonist Therapeutics to $118 From $112, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2633783139","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633783139?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:52","pubTimestamp":1778075536,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) has an average rating of buy and mean price target of $116.31, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633613519","title":"Protagonist Therapeutics Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2633613519","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633613519?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:57","pubTimestamp":1778072220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTGX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 06, 2026 08:57 ET (12:57 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633003669","title":"Barclays Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633003669","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633003669?lang=en_us&edition=fundamental","pubTime":"2026-05-06 16:41","pubTimestamp":1778056887,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on Protagonist Therapeutics, with a price target of $119.00. Accordi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-buy-rating-for-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-buy-rating-for-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protagonist-inc.com","stockEarnings":[{"period":"1week","weight":0.0536},{"period":"1month","weight":0.1062},{"period":"3month","weight":0.096},{"period":"6month","weight":0.2951},{"period":"1year","weight":1.0185},{"period":"ytd","weight":0.2759}],"compareEarnings":[{"period":"1week","weight":0.0214},{"period":"1month","weight":0.0031},{"period":"3month","weight":0.123},{"period":"6month","weight":0.0887},{"period":"1year","weight":0.24},{"period":"ytd","weight":0.0866}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.030975},{"month":2,"riseRate":0.5,"avgChangeRate":0.004927},{"month":3,"riseRate":0.5,"avgChangeRate":0.077907},{"month":4,"riseRate":0.2,"avgChangeRate":-0.1188},{"month":5,"riseRate":0.7,"avgChangeRate":0.186258},{"month":6,"riseRate":0.8,"avgChangeRate":0.096298},{"month":7,"riseRate":0.555556,"avgChangeRate":0.002773},{"month":8,"riseRate":0.777778,"avgChangeRate":0.16209},{"month":9,"riseRate":0.5,"avgChangeRate":0.00523},{"month":10,"riseRate":0.4,"avgChangeRate":0.039581},{"month":11,"riseRate":0.6,"avgChangeRate":0.076941},{"month":12,"riseRate":0.5,"avgChangeRate":0.014044}],"exchange":"NASDAQ","name":"Protagonist Therapeutics","nameEN":"Protagonist Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Protagonist Therapeutics(PTGX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Protagonist Therapeutics,PTGX,Protagonist Therapeutics股票,Protagonist Therapeutics股票老虎,Protagonist Therapeutics股票老虎国际,Protagonist Therapeutics行情,Protagonist Therapeutics股票行情,Protagonist Therapeutics股价,Protagonist Therapeutics股市,Protagonist Therapeutics股票价格,Protagonist Therapeutics股票交易,Protagonist Therapeutics股票购买,Protagonist Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Protagonist Therapeutics(PTGX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}